medigraphic.com
Anales de la Sociedad Mexicana de Oftalmología y Archivos de la Asociación Para Evitar la Ceguera en México

2009, Number 1

<< Back Next >>

Rev Mex Oftalmol 2009; 83 (1)

Control sistémico de una población diabética al momento de su ingreso a un centro oftalmológico de referencia

Lesso-Zamora J, Favier-González C, Sáenz VSM, Estrada-Rodríguez JL

Language: Spanish
References: 29
Page: 11-14
PDF size: 93.02 Kb.


ABSTRACT

Objective: To know systemic and ophthalmologic conditions that displays the patients with diabetes at the time of the first consultation in an ophthalmologic center of reference.
Material and methods: Observational and prospective study including patients of first time with diabetes mellitus type 2. Glucose levels, glycosylated hemoglobin, lipoprotein profile, microalbuminury, systemic arterial tension and complete ophthalmologic exploration was made in all patients.
Results: On 70 patients, glycemia average was 166.9 mg/dl, glycosylated hemoglobin average was 8.8% and microalbuminuria was found in 25 patients (35.7%). Hypercholesterolemia and hipertrigliceridemia was found in 44.3% and 40% of patients respectively. HDL cholesterol levels were 40 mg/dl or less in 84.3% of the patients. 51.4% of the patients affirmed to be hypertensive. Of them, 75% presented uncontrolled numbers of arterial tension. Of 140 eyes, 98 (70%) displayed diabetic retinopathy of which 33 (33.6%) correspond to nonproliferative retinopathy, 59 (60.2%) to proliferative retinopathy and 6 (6.1%) to inactivate photocoagulated retinopathy.
Conclusions: The studied population emphasizes the systemic factors of risk in the development and evolution of diabetic retinopathy. The results show the importance in the detection of these factors by ophthalmologist.


REFERENCES

  1. Palmer PF. Diabetic Retinopathy. Diabetes 1977; 26:703-709.

  2. McCulloch DK. Pathogenesis and natural history of diabetic retinopathy. 2007 UpToDate. Fuente: http: //www.utdol.com/utd/content/topic.do?topicKey=diabetes123

  3. The Diabetes Control and Complications Trial Research Group: The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes 1995; 44(8):968–983.

  4. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long- term complications in insulindependent diabetes mellitus. New Eng J Med 1993; 329(14):977-986.

  5. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. Arch Ophthalmol 1995; 113:36-51.

  6. Klein R, Klein BE y cols. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Ten-year incidence and progression of diabetic retinopathy. Arch Ophthalmol 1994; 112 (9):1217-1228.

  7. United Kingdom Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352(9131):837-853.

  8. Klein R, Klein BE y cols. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 1984; 102:527-532.

  9. Agardh E, Torffvit O, Agardh CD. Putative risk factors associated with retinopathy in patients with diabetes diagnosed at or alter 30 years of age. Diabetic Med 1989; 618:724-727.

  10. Gillow JT, Gibson JM, Dodson PM. Hypertension and diabetic retinopathy- what’s the story? Br J Ophthalmol 1999; 83:1083-1087.

  11. Dodson PM. Diabetic retinopathy: treatment and prevention. Diabetes and Vascular Disease Research 2007; 4(3):9-11.

  12. Modificación a la Norma Oficial Mexicana NOM-015-SSA2-1994, para la prevención, tratamiento y control de la diabetes mellitus en la atención primaria para quedar como Norma Oficial Mexicana NOM-015-SSA2-1994, para la prevención, tratamiento y control de la diabetes.

  13. Norma Oficial Mexicana NOM-037-SSA2-2002, para la prevención, tratamiento y control de las dislipidemias.

  14. Norma Oficial Mexicana NOM-030-SSA2-1999, para la prevención, tratamiento y control de la hipertensión arterial.

  15. Boccalandro C, Orlander P, Rey-Joly C. Diabetes mellitus y retinopatía diabética. En: Bonafonte S. Retinopatía diabética. 2ª ed. Madrid, Elsevier, 2006. pp. 15-26.

  16. Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final Report. Circulation 2002; 106:3143–21.

  17. Kinosian B, Glick H, Preiss L, Puder KL. Cholesterol and coronary heart disease: predicting risks in men by changes in levels and ratios. J Investig Med 1995; 43:443-50.

  18. Iltz JL, Campbell RK. Rastreo de microalbuminuria en pacientes con diabetes mellitus. Fuente: URL: http://www.hospitalitaliano.org.ar/sanjusto/index.php

  19. Harada T, Tanabe Y, Kojima K y cols. Glycosilated hemoglobin and control of diabetic retinopathy. J Fr Ophthalmol 1985; 85(4):315-319.

  20. Klein BEK, Moss SE, Klein R y cols. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XIII. Relationship of serum cholesterol to retinopathy and hard exudates. Ophthalmology 1991; 98:1261-1265.

  21. Chantry KH, Klein ML, Chew EY y cols. III. Early Treatment Diabetic Retinopathy Study Research Group: Associations of serum lipids and retinal hard exudates in patients enrolled in the Early Treatment Diabetic Retinopathy Study. Invest Ophthalmol Vis Sci 1989; 30:434.

  22. Braunwald E, Fauci AS, Kasper DL y cols. Harrison. Principios de Medicina Interna. 15ª ed. México, McGraw-Hill, 2002.

  23. Matsushima C, Wakabayashi Y, Iwzmoto T y cols. Relationship between retinal vein occlusion anda carotid artery lesions. Retina 2007; 27(8):1038-1043.

  24. United Kingdom Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS 38. BMJ 1998; 317(7160):703-713.

  25. Manaviat MR, Afkhami M, Shoja MR. Retinopathy and microalbuminuria in tipe II diabetic patients. BMC Ophthalmol 2004; 1:4-9.

  26. Boelter MC, Gross JL, Canani LH y cols. Proliferative diabetic retinopathy is associated with microalbuminuria in patients with type 2 diabetes. Braz J Med Biol Res 2006; 39(8):1033- 1039.

  27. Bonafonte S, Garcia CA. Epidemiología de la retinopatía diabética. En: Bonafonte S. Retinopatía diabética. 2ª edición. Madrid, Elsevier, 2006. pp. 61-72.

  28. Klein R, Klein BE, y cols. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. IV. Diabetic macular edema. Ophthalmology 1984; 1464-1474.

  29. Breshnick GH. Diabetic maculopathy, a critical review highlighting diffuse macular edema. Ophthalmology 1983; 90:1301-1317.




2020     |     www.medigraphic.com